Every drug therapy entails inconvenience, risk of complications, and costs-both economic and psychological. A compelling reason is therefore necessary to initiate and maintain therapy. The burden of proof lies with the prescriber.
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Nearly all successful randomized controlled trials in multiple sclerosis (MS) enrolled relatively young, relatively unimpaired patients with a history of recent relapses or new magnetic resonance imaging (MRI) lesions (for a succinct visual summary, see the following link: http://www.msdiscovery.org/ MStrials-baseline). In these patients, disease-modifying therapies (DMTs) decreased rates of relapses and, in some instances, short-term disability progression. But is it reasonable to prescribe DMTs to MS patients for whom drug efficacy has never been demonstrated, such as older MS patients, very disabled patients, or patients who do not evidence focal inflammatory activity for a prolonged period?
It may be tempting to infer DMTs' efficacy beyond the typical trial population, but such an extrapolation is unwarranted. Studies document a continuous decline in inflammatory activity with age, and the need for anti-inflammatory therapy declines accordingly. Analysis of 2476 white-matter MS plaques showed that the proportion of early-active lesions decreased from 75% within 1 year of symptom onset to nearly 0 after 30 years of disease. 1 Among patients who entered the secondary progressive phase, nearly all lesions were either inactive or smoldering. 1 Cerebrospinal fluid (CSF) biomarkers of inflammation and acute axonal injury also decline with age. MS patients older than 54 years had "consistently lower values for all the analyzed CSF markers" than younger patients. 2 It has been suggested that the decrease in central nervous system (CNS) inflammation may be due to "immunosenescence," such as diminished T-cell function with age.
These neuro-immunologic and neuro-pathologic data are in agreement with observational studies. The frequency of gadolinium enhancement on brain MRI in untreated MS patients decreased from 55% among the 20-30 year olds to 12% in the 50 years and older group (p < 0.0001). 3 Age was the most significant predictor of enhancement in a multivariable logistic regression; the probability of enhancement on brain MRI decreased by 36% for each additional decade. 3 Deceleration in the rate of lesion formation across the life-span paralleled the deceleration in relapse rate, which peaked in the twenties and thirties and then declined by approximately 34% per decade. 4 Among patients older than 55 years, who had been in the progressive phase for 5 years more, the probability of a relapse was only 5%. 5
Is there a threshold of expected annualized relapse rate beyond which continuation of DMT would no longer be indicated? It may be difficult to formulate rigid rules in this regard, but clinicians could help their patients make the "to treat-or-not-to-treat" decision by framing the discussion in the context of the natural history studies, and pointing out that DMTs have never been shown to slow disease progression in older, non-relapsing patients.
An important caveat to the above is that not starting a DMT in a patient for whom its efficacy is unproven is not the same as stopping a DMT in the same patient. To illustrate: the clinical trial of natalizumab in secondary progressive multiple sclerosis (SPMS) did not meet either primary or secondary endpoints (NCT01416181), yet stopping natalizumab in nonrelapsing patients put them at considerable risk of disease rebound. 6 We must, therefore, seek real-life data that support the safety of discontinuing specific DMTs in selected patients.
The literature on "post-DMT" disease course is only beginning to emerge. Several retrospective studies have been published within the last year. French investigators reported outcomes in 100 SPMS patients, in whom interferon-beta (IFN-β) or glatiramer acetate was discontinued after a consultation with a neurologist. The relapse and disability progression rates before and after discontinuation remained similar. Out of 100 patients, 33% had experienced inflammatory activity (relapse or new lesion) within 3 years of discontinuation, but only 5 patients had relapses that resulted in sustained Expanded Disability Status Scale (EDSS) increase. The main predictors of post-discontinuation relapses were enhancing lesions on MRI within 3 years of discontinuation and lower disability (EDSS < 6). 7 A singlecenter US experience cited even lower rates of new lesions or relapses in patients who stopped DMT on their clinician's advice-11.7%. 8 This low rate may be due to relatively high median age in this cohort (61 years) and long period of disease quiescence prior to discontinuation (2-20 years). 8 A Swedish study considered patients who stopped therapy after at least 5 relapse-free years. Inflammatory activity upon discontinuation of first-line DMTs was seen in 19 out of 55 patients (33%) during mean follow-up of 4.6 years. However, among 15 patients who stopped natalizumab, 9 (66%) developed "recurrent inflammatory disease" within (median) 19 months, and of them, 5 had "disease rebound" (defined as a higher volume of new enhancing lesions than seen on any prior MRI). 6 This study highlights the need to assess the risk-benefit of drug discontinuation on an agent-by-agent basis.
Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS -YES
Austrian investigators sought to determine risk factors for relapses and disability progression in patients with relapsing MS who stopped IFN-β or glatiramer acetate mostly due to adverse events or patient preference. Relapses were observed in 98 out of 221 patients (44%) during the mean of 3.8 years of follow-up, but patients who were older than 45 years and had no enhancing lesions on brain MRI for 4 years or more had a hazard ratio of only 0.06 to suffer a relapse. 9 Disability progression after discontinuation was recorded in 46 patients (20.8%) and was associated with higher EDSS, longer disease duration, and age >45 years at discontinuation. 9
The analysis of an international MS registry, the MSBase, went beyond documenting relapses and progression upon stopping therapy. The authors compared disease course in "DMT stoppers" with propensity-score-matched "DMT stayers." 10 The risk of relapse among DMT stoppers was 34% during 4.9 years of follow-up, but time to relapse among patients who stopped first-line DMTs was the same as among patients who continued on the first-line DMT. Survival time to confirmed disability progression was shorter among DMT stoppers compared to stayers; this difference was driven by subset of patients with stable EDSS for 5 years prior to discontinuation. 10 Taken together, these studies indicate that it may be possible to identify a subset of patients in whom DMT discontinuation could be reasonably attempted. The most relevant factors will likely be patient's age; duration without relapses or MRI activity; whether patient entered progressive phase or not; and identity of the agent being discontinued.
The concept of DMT discontinuation in selected patients is biologically plausible and supported by observational studies. It remains to be seen whether it will withstand the test of a randomized discontinuation trial-DISCOMS (NCT03073603-that is scheduled to begin enrollment in the summer of 2017.
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Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS -NO W Oliver Tobin and Brian G Weinshenker
As we approach the 25th anniversary of the introduction of interferon beta-1b, the first disease-modifying therapy (DMT) for multiple sclerosis (MS), consensus has emerged that MS disease-modifying treatments are safe and favorably alter not only short-term but also long-term outcomes, 1-3 although not every study has reached this conclusion. 4 However, no consensus has been reached as to whether or when DMTs can be safely discontinued. Given that DMT for MS accounts for ~75% of the cost of care for a patient with MS who is on a DMT, an era of rapidly rising healthcare inflation makes addressing the issue of DMT discontinuation urgent.
It has been well documented that the frequency of attacks and magnetic resonance imaging (MRI)detected inflammatory disease activity declines with time when considering MS patients as a group. Accordingly, there is good reason to believe that DMT withdrawal might be possible for patients meeting certain criteria (e.g. a disease of long duration, the onset of secondary progressive MS (SPMS), lack of recent relapses, and lack of recent MRI activity). 5 However, disease heterogeneity precludes the confident determination of safety of medication withdrawal for individual patients. There are no prospective trials of discontinuation of DMT in MS, although one is in progress (NCT03073603).
Several studies have shown that patients with SPMS do not benefit from DMT. 6 Therefore, DMT withdrawal might be reasonably considered when SPMS supervenes in a patient with relapsing-remitting MS (RRMS). However, recent clinical trials of two potent DMTs, ocrelizumab in primary progressive MS (PPMS) 7 and siponimod in SPMS, 8 demonstrated slowed progression of disability, even in patients lacking MRI criteria for ongoing inflammatory disease activity. This suggests that even brain MRI detection of subclinical inflammatory activity fails to sensitively identify those who may benefit from a potent DMT. Cohort observational data support benefit of DMT early in the transition period from RRMS to SPMS, although only in patients with ongoing relapses during progression. 9
The definition of "stable" relapsing-remitting MS deserves some consideration. The AFFIRM, SENTINEL, and GLANCE studies of natalizumab and their subsequent open-label extensions with voluntary drug withdrawal in 2005 demonstrated a socalled "rebound" phenomenon of return of disease activity in previously stable patients. 10 A more recent
